Literature DB >> 17613943

Increased brain serotonin turnover in panic disorder patients in the absence of a panic attack: reduction by a selective serotonin reuptake inhibitor.

Murray Esler1, Elisabeth Lambert, Marlies Alvarenga, Florentia Socratous, Jeff Richards, David Barton, Ciaran Pier, Celia Brenchley, Tye Dawood, Jacqueline Hastings, Ling Guo, Deepak Haikerwal, David Kaye, Garry Jennings, Victor Kalff, Michael Kelly, Glen Wiesner, Gavin Lambert.   

Abstract

Since the brain neurotransmitter changes characterising panic disorder remain uncertain, we quantified brain noradrenaline and serotonin turnover in patients with panic disorder, in the absence of a panic attack. Thirty-four untreated patients with panic disorder and 24 matched healthy volunteers were studied. A novel method utilising internal jugular venous sampling, with thermodilution measurement of jugular blood flow, was used to directly quantify brain monoamine turnover, by measuring the overflow of noradrenaline and serotonin metabolites from the brain. Radiographic depiction of brain venous sinuses allowed differential venous sampling from cortical and subcortical regions. The relation of brain serotonin turnover to serotonin transporter genotype and panic disorder severity were evaluated, and the influence of an SSRI drug, citalopram, on serotonin turnover investigated. Brain noradrenaline turnover in panic disorder patients was similar to that in healthy subjects. In contrast, brain serotonin turnover, estimated from jugular venous overflow of the metabolite, 5-hydroxyindole acetic acid, was increased approximately 4-fold in subcortical brain regions and in the cerebral cortex (P < 0.01). Serotonin turnover was highest in patients with the most severe disease, was unrelated to serotonin transporter genotype, and was reduced by citalopram (P < 0.01). Normal brain noradrenaline turnover in panic disorder patients argues against primary importance of the locus coeruleus in this condition. The marked increase in serotonin turnover, in the absence of a panic attack, possibly represents an important underlying neurotransmitter substrate for the disorder, although this point remains uncertain. Support for this interpretation comes from the direct relationship which existed between serotonin turnover and illness severity, and the finding that SSRI administration reduced serotonin turnover. Serotonin transporter genotyping suggested that increased whole brain serotonin turnover most likely derived not from impaired serotonin reuptake, but from increased firing in serotonergic midbrain raphe neurons projecting to both subcortical brain regions and the cerebral cortex.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17613943     DOI: 10.1080/10253890701300904

Source DB:  PubMed          Journal:  Stress        ISSN: 1025-3890            Impact factor:   3.493


  18 in total

Review 1.  Maternal SSRIs experience and risk of ASD in offspring: a review.

Authors:  Zainab Fatima; Aqeela Zahra; Maria Ghouse; Xu Wang; Zonghui Yuan
Journal:  Toxicol Res (Camb)       Date:  2018-07-11       Impact factor: 3.524

2.  Investigation of a central nucleus of the amygdala/dorsal raphe nucleus serotonergic circuit implicated in fear-potentiated startle.

Authors:  B M Spannuth; M W Hale; A K Evans; J L Lukkes; S Campeau; C A Lowry
Journal:  Neuroscience       Date:  2011-01-26       Impact factor: 3.590

3.  Post-weaning social isolation of female rats, anxiety-related behavior, and serotonergic systems.

Authors:  Jodi L Lukkes; Glenn H Engelman; Naomi S Zelin; Matthew W Hale; Christopher A Lowry
Journal:  Brain Res       Date:  2012-01-12       Impact factor: 3.252

Review 4.  Stress-related serotonergic systems: implications for symptomatology of anxiety and affective disorders.

Authors:  Matthew W Hale; Anantha Shekhar; Christopher A Lowry
Journal:  Cell Mol Neurobiol       Date:  2012-04-07       Impact factor: 5.046

5.  Acute escitalopram but not contextual conditioning exerts a stronger "anxiogenic" effect in rats with high baseline "anxiety" in the acoustic startle paradigm.

Authors:  Robert Pettersson; Jakob Näslund; Staffan Nilsson; Elias Eriksson; S Melker Hagsäter
Journal:  Psychopharmacology (Berl)       Date:  2014-11-25       Impact factor: 4.530

Review 6.  Serotonergic innervation of the amygdala: targets, receptors, and implications for stress and anxiety.

Authors:  Esther Asan; Maria Steinke; Klaus-Peter Lesch
Journal:  Histochem Cell Biol       Date:  2013-03-15       Impact factor: 4.304

7.  Association of a polyadenylation polymorphism in the serotonin transporter and panic disorder.

Authors:  Sandeep Gyawali; Ryan Subaran; Myrna M Weissman; Dylan Hershkowitz; Morgan C McKenna; Ardesheer Talati; Abby J Fyer; Priya Wickramaratne; Phillip B Adams; Susan E Hodge; Carl J Schmidt; Michael J Bannon; Charles E Glatt
Journal:  Biol Psychiatry       Date:  2009-12-06       Impact factor: 13.382

8.  Platelet serotonin transporter function and heart rate variability in patients with panic disorder.

Authors:  Eun-Ho Kang; In-Soo Lee; Joo-Eon Park; Kyung-Jeong Kim; Bum-Hee Yu
Journal:  J Korean Med Sci       Date:  2010-03-19       Impact factor: 2.153

9.  Serotonin transporter polymorphisms and panic disorder.

Authors:  Johannes Schumacher; Jürgen Deckert
Journal:  Genome Med       Date:  2010-06-29       Impact factor: 11.117

Review 10.  Stress, depression and cardiovascular dysregulation: a review of neurobiological mechanisms and the integration of research from preclinical disease models.

Authors:  Angela J Grippo; Alan Kim Johnson
Journal:  Stress       Date:  2009-01       Impact factor: 3.493

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.